Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
cSVF for Post-COVID-19 Residual Lung Damage
NCT04326036Phase 1Unknown
- Start
- Mar 2020
- Primary completion
- Aug 2023
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of autologous adipose stromal vascular fraction in pulmonary fibrosis (PF), chronic obstructive pulmonary disease (COPD) and interstitial lung disease (ILD). Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 1 month. Status: unknown.
02
Drugs
autologous adipose stromal vascular fraction
03
Conditions
pulmonary fibrosis (PF)chronic obstructive pulmonary disease (COPD)interstitial lung disease (ILD)
Beyond the preview
Go deeper on NCT04326036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04326036.